| 000 | 01828 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517214135.0 | ||
| 264 | 0 | _c20190613 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1538-7445 | ||
| 024 | 7 |
_a10.1158/0008-5472.CAN-17-3932 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoh, Siang-Boon | |
| 245 | 0 | 0 |
_aMechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. _h[electronic resource] |
| 260 |
_bCancer research _c06 2018 |
||
| 300 |
_a3054-3066 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aCell Cycle Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCheckpoint Kinase 1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDNA Damage _xdrug effects |
| 650 | 0 | 4 |
_aDNA Replication _xdrug effects |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aNuclear Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aXenograft Model Antitumor Assays _xmethods |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aWallez, Yann | |
| 700 | 1 | _aDunlop, Charles R | |
| 700 | 1 | _aBernaldo de Quirós Fernández, Sandra | |
| 700 | 1 | _aBapiro, Tashinga E | |
| 700 | 1 | _aRichards, Frances M | |
| 700 | 1 | _aJodrell, Duncan I | |
| 773 | 0 |
_tCancer research _gvol. 78 _gno. 11 _gp. 3054-3066 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/0008-5472.CAN-17-3932 _zAvailable from publisher's website |
| 999 |
_c28366084 _d28366084 |
||